All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Is it possible to use different BCMA-targeted agents successively?
Featured
During the 19th International Myeloma Society Annual Meeting, the Multiple Myeloma Hub was pleased to speak to María-Victoria Mateos , University Hospital of Salamanca, Salamanca, ES. We asked, Is it possible to use different B-cell maturation antigen (BCMA)-targeted agents successively?
Is it possible to use different BCMA-targeted agents successively?
In this video, Mateos discusses the clinical outcomes of a cohort of 20 patients treated with different BCMA-targeted therapies sequentially. Mateos evaluates these outcomes in terms of minimal residual disease negativity rate, progression-free survival, and safety signals to come to a conclusion on the posed question.
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox